US Cancer Incidence, Mortality Show Overall Decline

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 5
Volume 8
Issue 5

WASHINGTON-Overall cancer incidence and mortality have continued to decline in the United States, but incidences of some cancers continue to rise, and significant differences in both incidence and mortality persist among different racial and ethnic groups.

WASHINGTON—Overall cancer incidence and mortality have continued to decline in the United States, but incidences of some cancers continue to rise, and significant differences in both incidence and mortality persist among different racial and ethnic groups.

Between 1990 and 1996, the national incidence rate declined an average of 0.9% per year, and mortality fell 0.6% per year, according to the “Annual Report to the Nation on the Status of Cancer, 1973-1996.” The study was prepared by the American Cancer Society, National Cancer Institute, and the Centers for Disease Control and Prevention (CDC).

Lung, prostate, breast, and colorectal cancer were the top four cancer incidence sites among the five populations studied—white, black, Hispanic, American Indian/Alaskan Native, and Asian/Pacific Islander. The same sites were the top four causes of cancer deaths in all groups, with one exception. Liver cancer replaced breast cancer in the mortality top four among Asians and Pacific Islanders.

Although breast cancer incidence has changed little during the 1990s, breast cancer mortality has declined about 2% per year. Colorectal cancer incidence and deaths continued to decline among both men and women. New cases and deaths have continued to rise for non-Hodgkin’s lymphoma, although less so in the 1990s than in the 1980s. And the incidence of melanoma continued to rise about 3% annually from 1990 to 1996, although mortality has remained constant.

Recent Videos
The addition of radioembolization to radiosensitizing chemotherapy may help concurrently treat patients with liver tumors and disease outside the liver.
In neuroendocrine tumor management, patients with insulinoma may be at risk of severe hypoglycemia following receipt of GLP-1 receptor agonists.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
4 experts are featured in this series.
4 experts are featured in this series.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
7 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
Related Content